Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.

For headache, lemborexant C av,ss was a weakly significant predictor (at the P < .05 level); however, the probability of experiencing this adverse event was noted to decrease with increasing exposure under the linear logit model (Table 4 ).

also in 1,387 other papers

The box plots illustrate the relationship of individual predictions of clearance versus categorized age (adult versus elderly > 65 year old), BMI, and ALP, with all covariates illustrating a decreasing trend in clearance (increasing exposure).

also in 47,180 other papers

This residual error modification resulted in a highly significant reduction in the OFV value compared with a model with an additive/proportional combined residual variability.

also in 132,142 other papers